Literature DB >> 12168930

COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome.

Sven Petersen1, Gunter Haroske, Gunter Hellmich, Klaus Ludwig, Cordula Petersen, Wolfgang Eicheler.   

Abstract

BACKGROUND: Increasing evidence suggests that COX-2 promotes carcinogenesis but it is controversial as to whether COX-2 expression is a prognostic factor for rectal carcinoma.
MATERIALS AND METHODS: Data of 62 consecutive patients with rectal carcinoma in UICC-stages I-III, which were curatively resected between 1995 and 1996, were analyzed. The paraffin-embedded tumor samples were stained for COX-2 expression. A labeling index of stained cells was calculated and the median COX- 2 labeling index was used as the cut-offpoint for statistical analysis.
RESULTS: The median labeling index was 0.58 (SD +/- 0.25). The Chi-square test revealed no correlation between COX-2 overexpression and the established prognostic factors. In the univariate analysis, COX-2 did not show significance according to the endpoints, local recurrence (p=0.41), disease-specific survival (p=0.28) or overall-survival (p=0.69). In contrast increased COX-2 level was a significant prognostic factor for pulmonary metastasis (p=0.04). DISCUSSION: COX-2 expression lacked significance as a prognostic factor for local control and survivaL However, there is evidence that COX-2 might be linked to an increased risk of hematogenous metastatic spread.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168930

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Inflammation and cancer.

Authors:  Noemí Eiró; Francisco J Vizoso
Journal:  World J Gastrointest Surg       Date:  2012-03-27

Review 2.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

3.  Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.

Authors:  Annelies Debucquoy; Laurence Goethals; Louis Libbrecht; Christiaan Perneel; Karel Geboes; Nadine Ectors; William H McBride; Karin Haustermans
Journal:  Int J Colorectal Dis       Date:  2008-12-03       Impact factor: 2.571

4.  Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: prognostic value and effects of preoperative radio (chemo) therapy.

Authors:  Annelies Debucquoy; Louis Libbrecht; Valerie Roobrouck; Laurence Goethals; William McBride; Karin Haustermans
Journal:  Eur J Cancer       Date:  2008-03-18       Impact factor: 9.162

5.  Aspirin use and survival after diagnosis of colorectal cancer.

Authors:  Andrew T Chan; Shuji Ogino; Charles S Fuchs
Journal:  JAMA       Date:  2009-08-12       Impact factor: 56.272

6.  The role of COX-2 in rectal cancer treated with preoperative radiotherapy.

Authors:  Hanifa Bouzourene; Pu Yan; Dominique Sandmeier; Abderrahim Zouhair; Maurice Matter; Henri Vuilleumier; Philippe Coucke
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

7.  Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.

Authors:  Sung Chul Lim; Hoon Cho; Tae Bum Lee; Cheol Hee Choi; Young Don Min; Sung Soo Kim; Kyung Jong Kim
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.